Company / Total Debt
Cytokinetics Total Debt History
FY2016-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest Total Debt
$246.4M
FY2025
5-year range
$47.4M / $649.6M
FY2021-FY2025
Trend
-60.2%
vs FY2024
Sector context
#41 of 83
Health Care
What the data says
At $246M, Cytokinetics's total debt ranks #43 of 83 in the Health Care sector. Total Debt has declined for 3 consecutive years, from $650M in FY2022 to $246M in FY2025.
Based on SEC 10-K filings.
$246M in FY2025 with a 5-year CAGR of +39.8%.
Improved from $639M to $246M over the past 2 years.
Health Care sector context is included.
Total Debt over time
Growth rates
- 3-Year CAGR
- -27.6%
- 5-Year CAGR
- +39.8%
- 10-Year CAGR
- -
Sector benchmark
#43 of 83 in Health CareTop 51% of 83This company $246.4M Sector average $6.2B
▼
-96.0% below sector average
Key checks
Key Insights
- Cytokinetics's total debt has declined for 3 consecutive years.
- 5-year CAGR of +39.8%, indicating consistent growth.
- In FY2025, total debt decreased 60.2% year-over-year.
- Ranks #41 out of 83 companies in the Health Care sector.
Company context
Key Data Points
- Altman Z-Score -3.12 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | Total DebtValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $246.4M | -60.2% |
| FY2024 | $619.5M | -3.1% |
| FY2023 | $639.3M | -1.6% |
| FY2022 | $649.6M | +1271.3% |
| FY2021 | $47.4M | +2.5% |
| FY2020 | $46.2M | +2.6% |
| FY2019 | $45.1M | +6.2% |
| FY2018 | $42.4M | +33.5% |
| FY2017 | $31.8M | +6.3% |
| FY2016 | $29.9M | +104.1% |
As of FY2025 · SEC 10-K · Updated Jul 2, 2026